How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

358 results for

bell's palsy guideline

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Treatment of Pediatric Diaphyseal Femur Fractures

Treatment of Pediatric Diaphyseal Femur Fractures TREATMENT OF PEDIATRIC DIAPHYSEAL FEMUR FRACTURES EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors June 12, 2015 AAOS v 1.0 061909 2015 REPORT FOR THE REISSUE OF THE 2009 CLINICAL PRACTICE GUIDELINE ON THE TREATMENT OF PEDIATRIC DIAPHYSEAL FEMUR FRACTURES “This guideline is greater than 5 years old and is reviewed every five years. New studies have been published since (...) this guideline was developed, however the AAOS has determined that these studies are not sufficient to warrant changing the guideline at this time. The information contained in this guideline provides the user with the best evidence available at the time this guideline was published.” OVERVIEW OF 2015 UPDATES TO THE 2009 ORIGINAL GUIDELINE 1) Addition of the Shemshaki, et al, 2011 study findings to Elastic Intramedullary Nails. 2) Updated strength of recommendation language to match current AAOS guideline

2015 American Academy of Orthopaedic Surgeons

102. Lateral Patellar Dislocations and Instability ? Post-Operative Management

Lateral Patellar Dislocations and Instability ? Post-Operative Management Evidence-Based Care Guideline for Post-Operative Management of Lateral Patellar Dislocations and Instability in children and adults aged 8-25 years Guideline 46 Copyright © 2015 Cincinnati Children's Hospital Medical Center; all rights reserved. Page 1 of 38 James M. Anderson Center for Health Systems Excellence Evidence-Based Care Guideline Post-Operative Management of Lateral Patellar Dislocations and Instability (...) ., Cerebral Palsy, Down Syndrome) ? With patellofemoral re-alignment techniques as part of the surgical procedure (e.g. lateral retinacular release, tibial tubercle re-alignment) ? With lateral patellar instability currently being managed conservatively rather than through surgical intervention Target Users Include but are not limited to (in alphabetical order): ? Athletic Trainers ? Coaches ? Nurse Practitioners ? Other healthcare professionals ? Patients and families ? Physical Therapists and Physical

2015 Cincinnati Children's Hospital Medical Center

103. Acute Pain Management: Scientific Evidence

and implementation of clinical practice guidelines . https:// www.nhmrc.gov.au/guidelines-publications/cp30 Accessed 29 August 2014. painaustralia (2010) National Pain Strategy. Available from Painaustralia at: www.painaustralia.org.au Accessed 24 October 2015. Reardon DP , Anger KE, Szumita PM (2015) Pathophysiology, assessment, and management of pain in critically ill adults. Am J Health Syst Pharm 72(18):1531–43. Shipton EA (2014a) The transition of acute postoperative pain to chronic pain: Part 1 - Risk (...) , the Malaysian Association for the Study of Pain, the New Zealand Pain Society, the Pain Association of Singapore, the Royal Australasian College of Physicians, the Royal Australian and New Zealand College of Psychiatrists and the Royal Australasian College of Surgeons — and recommended to its members by the American Academy of Pain Medicine. Guidelines should be revised as further evidence accumulates (ideally every 5 years), and as there has been a continuing and substantial increase in the quantity

2015 Clinical Practice Guidelines Portal

104. Trumenba - meningococcal group b vaccine (recombinant, adsorbed)

, in vitro Relative Antigenicity Method (IVRA), purity, protein concentration Assessment report EMA/CHMP/232746/2017 Page 16/139 determination, Polysorbate 80 (to calculate PS80 to protein molar ratio), residual DNA and residual host cell protein (HCP). The analytical methods used have been adequately described and non-compendial methods appropriately validated in accordance with ICH guidelines. A summary of all the analytical procedures and associated validation reports is provided. Batch analysis Batch (...) of a modified rabbit pyrogenicity test has been justified. Non-compendial methods are described in sufficient detail and validated in conformance with ICH guidelines. The in vivo potency assay (IVPA) is used to determine the immunogenicity of bivalent rLP2086 finished product. Batch analysis The batch analyses data for MnB bivalent rLP2086 finished product lots manufactured at full commercial scale have been provided. All data meet the specifications in place at the time of release. Stability of the product

2017 European Medicines Agency - EPARs

105. Monitoring your baby during labour: A decision aid for women having a vaginal birth

with a cardiotocograph for 20 to 30 minutes when they first arrived at their chosen place of birth in labour. Some hospitals still suggest that all women are monitored when they first arrive while others do not. Studies have shown that there is no evidence of benefit for this practice for low risk women, therefore it is no longer recommended. [9] Photo courtesy of Herston Multimedia Unit 6You can choose when and how your baby is monitored during labour. Hospitals or birth centres usually have guidelines for care (...) providers about when intermittent and continuous monitoring is used. Different care providers might also vary in their preferences for monitoring in different circumstances [7]. You might like to ask your care provider about these guidelines at your chosen place of birth. In normal labour when no complications are expected, intermittent monitoring of the baby’s heart is usually offered. Low risk women may not always be able to choose to have continuous monitoring as studies show that continuous

2015 EUnetHTA

106. Using a bath or pool during first stage labour: A decision aid for women having a vaginal birth

a woman is immersed in water. Sometimes a woman’s care provider may suggest she gets out of the water while the monitoring is performed. You can ask your care provider if your planned place of birth has monitoring machines that are designed to be used during water immersion. If you are using water immersion, your hospital or birth centre may have guidelines about using a bath or pool during labour (e.g. about the temperature of the water and whether it is suitable to use the pool if your waters have (...) broken before 37 weeks). You can ask your care provider for more information about guidelines for water immersion at your planned place of birth . Option 1 Option 2 What happens if I choose not to use a bath or pool? What happens if I choose a bath or pool? 7Some hospitals or birth centres do not have the facilities or staff training available for using a bath or pool during labour. Your might like to ask your care provider about the facilities available to you at your planned place of birth. In some

2015 EUnetHTA

107. Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants up to Six Months of Age

Detection and Nonoperative Management of Pediatric Developmental Dysplasia of the Hip in Infants up to Six Months of Age i DETECTION AND NONOPERATIVE MANAGEMENT OF PEDIATRIC DEVELOPMENTAL DYSPLASIA OF THE HIP IN INFANTS UP TO SIX MONTHS OF AGE EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors September 5, 2014 This guideline has been endorsed by the following organizations: ii Disclaimer This Clinical Practice Guideline (...) was developed by an AAOS clinician volunteer Work Group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician’s

2014 American Academy of Orthopaedic Surgeons

108. Perinatal care at the threshold of viability

Perinatal care at the threshold of viability Perinatal care at the threshold of viability Queensland Clinical Guideline: Perinatal care at the threshold of viability Refer to online version, destroy printed copies after use Page 2 of 35 Document title: Perinatal care at the threshold of viability Publication date: September 2014 Document number: MN14.32-V1-R19 Document supplement: The document supplement is integral to and should be read in conjunction with this guideline. Amendments Full (...) version history is supplied in the document supplement. Amendment date: New document Replaces document: New document Author: Queensland Clinical Guidelines Audience: Health professionals in Queensland public and private maternity services Review date: September 2019 Endorsed by: Queensland Clinical Guidelines Steering Committee Statewide Maternity and Neonatal Clinical Network Contact: Email: Guidelines@health.qld.gov.au URL: www.health.qld.gov.au/qcg Disclaimer These guidelines have been prepared

2014 Queensland Health

109. Diagnosis and Treatment of Adult Isthmic Spondylolisthesis

Diagnosis and Treatment of Adult Isthmic Spondylolisthesis This clinical guideline should not be construed as including all proper methods of care or excluding or other acceptable methods of care reason- ably directed to obtaining the same results. The ultimate judgment regarding any specific procedure or treatment is to be made by the physi- cian and patient in light of all circumstances presented by the patient and the needs and resources particular to the locality or institution. 1 Introduct (...) Ion /Gu Idel Ine Methodolo Gy Diagnosis and Treatment of Adult Isthmic Spondylolisthesis | NASS Clinical Guidelines NASS Evidence-Based Clinical Guidelines Committee D. Scott Kreiner, MD Committee Co- Chair and Natural History Section Chair Jamie Baisden, MD Diagnosis/Imaging Section Chair Daniel Mazanec, MD Medical/Interventional Treatment Section Chair Rakesh Patel, MD Surgical Treatment Section Chair Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care Diagnosis and Treatment

2014 North American Spine Society

110. Management of Thyroid Cancer

Management of Thyroid Cancer CLINICAL ENDOCRINOLOGY VOLUME 81 SUPPLEMENT 1 JULY 2014 THE CLINICAL JOURNAL OF THE SOCIETY FOR ENDOCRINOLOGY AND THE ENDOCRINE SOCIETY OF AUSTRALIA British Thyroid Association Guidelines for the Management of Thyroid CancerGuidelines for the management of thyroid cancer Third edition British Thyroid Association July 2014 Perros P, Colley S, Boelaert K, Evans C, Evans RM, Gerrard GE, Gilbert JA, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V , Newbold KL (...) , Taylor J, Thakker RV , Watkinson J, Williams GR cen_frontmatter.indd i cen_frontmatter.indd i 6/27/2014 3:52:19 PM 6/27/2014 3:52:19 PMii Acknowledgements Grateful thanks are expressed to the many reviewers of these guidelines. These included leading international experts in thyroid cancer, hospital specialists, and general practitioners. They devoted much time and care to considering the document and their recommendations and suggestions for improvements were most valuable. Special thanks to Dr

2014 British Thyroid Association

111. Transitions of Care for Children with Special Health Care Needs

practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied. This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted, for which further reproduction is prohibited without the specific permission of copyright holders. Persons using assistive technology may (...) transition processes and medical management of adults with childhood-onset chronic diseases. 24,28-30 Additionally, CSHCN face broader challenges, including issues related to insurance, entitlements, guardianship, and eligibility for adult community-based services. 2,31 Nonetheless, several guidelines, panels, and other groups coalesce around the need for good transition care for this population in particular. Healthy People 2010 32 includes a goal that all young people with special health care needs

2014 Effective Health Care Program (AHRQ)

112. Perinatal care at the threshold of viability

Perinatal care at the threshold of viability Perinatal care at the threshold of viability Queensland Clinical Guideline: Perinatal care at the threshold of viability Refer to online version, destroy printed copies after use Page 2 of 35 Document title: Perinatal care at the threshold of viability Publication date: September 2014 Document number: MN14.32-V1-R19 Document supplement: The document supplement is integral to and should be read in conjunction with this guideline. Amendments Full (...) version history is supplied in the document supplement. Amendment date: New document Replaces document: New document Author: Queensland Clinical Guidelines Audience: Health professionals in Queensland public and private maternity services Review date: September 2019 Endorsed by: Queensland Clinical Guidelines Steering Committee Statewide Maternity and Neonatal Clinical Network Contact: Email: Guidelines@health.qld.gov.au URL: www.health.qld.gov.au/qcg Disclaimer These guidelines have been prepared

2014 Clinical Practice Guidelines Portal

113. Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer

ovary cells or any component of the atezolizumab formulation Patients with prior allogeneic stem cell or solid organ transplantation History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis History of idiopathic (...) to ASCO/CAP guidelines 2013 [defined as IHC 3+ or ISH positive (by gene copy number or HER2 gene/CEP17 ratio of 2 or greater)] Known estrogen (ER) and progesterone receptor (PgR) Availability of a representative paraffin-embedded (FFPE) tumor block taken at diagnostic biopsy for central confirmation of HER2 eligibility, for assessment of ER, PgR, Ki67 and PD-L1 expression and for biomarker evaluation is mandatory. Note: the diagnostic biopsy of the breast lesion may have been taken before the required

2018 Clinical Trials

114. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

[Internet]. Bethesda (MD): ; 2002-. Search term Unusual Cancers of Childhood Treatment (PDQ®) Health Professional Version PDQ Pediatric Treatment Editorial Board . Published online: January 31, 2019. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of unusual cancers of childhood. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines (...) , pediatric nurse specialists, social workers, and others to ensure that children receive treatment, supportive care, and rehabilitation that will achieve optimal survival and quality of life. (Refer to the PDQ summaries for specific information about supportive care for children and adolescents with cancer.) Guidelines for pediatric cancer centers and their role in the treatment of pediatric patients with cancer have been outlined by the American Academy of Pediatrics.[ ] At these pediatric cancer

2016 PDQ - NCI's Comprehensive Cancer Database

115. Diagnosis and Treatment of Peripheral Artery Diseases

Diagnosis and Treatment of Peripheral Artery Diseases ESC GUIDELINES ESC Guidelines on the diagnosis and treatment of peripheral artery diseases Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC) Endorsed by: the European Stroke Organisation (ESO) Authors/Task Force Members: Michal Tendera (...) ), Horst Sievert (Germany), Marc van Sambeek (The Netherlands), Thomas Zeller (Germany). ESC Committee for Practice Guidelines (CPG): Jeroen Bax (CPG Chairperson) (The Netherlands), Angelo Auricchio (Switzerland), Helmut Baumgartner (Germany), Claudio Ceconi (Italy), Veronica Dean (France), Christi Deaton (UK), Robert Fagard (Belgium), Christian Funck-Brentano (France), David Hasdai (Israel), Arno Hoes (The Netherlands), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Theresa McDonagh (UK), Cyril

2011 European Society of Cardiology

116. Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer

associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic (...) may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines Patient must have an Eastern Cooperative Oncology Group

2017 Clinical Trials

117. Lactoferrin Infant Feeding Trial

: Randomization to 36 weeks corrected gestation or to transfer/discharge if earlier. ] Hospital mortality or major morbidity at 36 weeks corrected gestation defined as: Brain injury on ultrasound Chronic lung disease Necrotizing enterocolitis (Bell stage II or higher ) Late onset sepsis (≥ 72 hours of life, culture proven), or Retinopathy of prematurity treated according to local guidelines before discharge from hospital. Secondary Outcome Measures : Incidence of all-cause in-hospital mortality [ Time Frame (...) gestation ] Incidence of death by 24 months corrected age or the presence of major neurodevelopmental outcomes at 24 months corrected age, as defined: (i) visual (cannot fixate/ legally blind, or corrected acuity <6/60 in both eyes), or hearing impairment (requiring a hearing aid or cochlear implants); (ii) cerebral palsy with an inability to walk unassisted; (iii) major developmental delay involving cognition or speech (composite score < 85 for cognition or language on assessment) Eligibility Criteria

2017 Clinical Trials

118. APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

evaluation due to tumor involvement of the central nervous system (CNS). History of Bell's palsy Active rheumatoid arthritis (RA), active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation Active infection requiring systemic antibiotic/ antifungal medication, Known or suspected Wilson's Disease. Prior treatment with IAP inhibitors History of hypersensitivity to paclitaxel, or any therapeutic antibody Has an active autoimmune disease (...) : Maximum Tolerated Dose (MTD) [ Time Frame: 18-24 months ] Patients with APG-1387 treatment related adverse events (AE), serious adverse events (SAE) will be assessed according NCI CTCAE Version 4.0 Secondary Outcome Measures : Anti-tumor effects of APG-1387 as a single agent [ Time Frame: 18-24 months ] Response will be evaluated every 2 cycles (8 weeks), according to the revised RECIST Guideline, Version 1.1 or the Revised Response Criteria for Malignant Lymphoma (Cheson, 2007). Pharmacokinetic

2017 Clinical Trials

119. Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment; autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre (...) for translational medicine studies Patient must be offered the opportunity to participate in tissue and blood banking for future studies Patient must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines As a part of the Oncology Patient Enrollment Network (OPEN) registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional

2017 Clinical Trials

120. Cobimetinib and Atezolizumab in Advanced Rare Tumors

but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis a. Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible. b. Patients with controlled Type 1 diabetes mellitus on a stable (...) nature of this study and must be willing to give written informed consent in accordance with institutional and federal guidelines. Patients must be able to comply with the requirements and assessments of the study protocol Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. Effective methods of contraception are defined as those that result in a low failure rate (i.e., less than 1

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>